MannKind Corporation ($MNKD) Stock Hub: Q2 2026 Earnings, Afrezza, FUROSCIX and Nintedanib DPI

01 Q2 revenue reached $109.4M, but launch spending kept operating leverage out of reach

MannKind reported 43% year-over-year revenue growth in Q2 2026, led by Furoscix, collaboration revenue and Tyvaso DPI royalties. The mix improved strategically, but Afrezza fell 7%, SG&A rose 84%, and adjusted net income swung to a $2.7 million loss. Positive INFLO-1 safety and tolerability data add pipeline validation; the near-term investment case now depends on commercial execution and cash discipline.

A complete English-language MannKind earnings hub covering Q2 2026 revenue quality, Furoscix and ReadyFlow execution, pediatric Afrezza adoption, Tyvaso DPI royalties, positive INFLO-1 safety data, cash, debt, dilution and the next operating catalysts.

Editorial research for informational and educational purposes only. This is not personalized investment advice, medical advice or a recommendation to buy, sell or hold any security. Clinical and regulatory information should be checked against primary sources, and healthcare decisions belong exclusively to qualified professionals.

02 Executive Summary: Revenue Accelerated, but the Earnings Quality Test Got Harder

MannKind reported Q2 2026 revenue of $109.4 million, up 43% year over year and 21% sequentially. The growth was broad at the consolidated level: commercial product sales rose to $42.0 million, collaboration and services revenue reached $35.0 million, and royalties were $32.4 million. The headline is strong, but the mix matters. Furoscix supplied the owned-product acceleration, while United Therapeutics still accounted for approximately 61% of consolidated revenue.

Furoscix revenue was $22.2 million, up 43% from Q1, and management maintained full-year guidance of $110 million to $120 million. That guidance is the quarter’s central execution test. First-half Furoscix revenue was only $37.7 million, so MannKind needs roughly $72.3 million to $82.3 million in the second half—about 1.9 to 2.2 times the entire first-half total. ReadyFlow can improve usability and commercial mix, but its August launch must ramp quickly for the target to remain credible.

Afrezza revenue fell 7% year over year to $17.0 million despite the May 29 pediatric approval. Management described encouraging early physician engagement, including approximately 450 new prescribers since launch, but adult demand was soft and the pediatric contribution was partial. This creates a useful distinction: label expansion is de-risked, while commercial adoption is not.

Profitability did not follow revenue. SG&A increased 84% to $58.3 million as MannKind funded the Furoscix integration, ReadyFlow launch and pediatric Afrezza expansion. GAAP net loss was $19.0 million, or $0.06 per share, while adjusted net loss was $2.7 million, or $0.01 per share. Several accounting items widened the GAAP loss, but the negative adjusted result confirms that the deterioration was not purely non-cash.

Pipeline risk improved with positive INFLO-1 Phase 1b safety and tolerability data for nintedanib DPI. No serious adverse events, bronchospasm or dose-related discontinuations were reported in 27 patients with idiopathic pulmonary fibrosis. Cross-study plasma exposure appeared six to eight times higher than published nebulized-formulation data at comparable doses, but that was not a head-to-head efficacy comparison. INFLO-2 remains the program’s more meaningful development test.

03 Latest Development: ReadyFlow Moves From PDUFA to Commercial Launch

The FDA approved Furoscix ReadyFlow on July 24, 2026, two days before the target action date. According to the company, ReadyFlow is the first and only autoinjector delivering subcutaneous furosemide with IV-equivalent exposure based on pharmacokinetic and pharmacodynamic comparisons. The device delivers a full 80 mg/mL dose in ten seconds or less, compared with approximately five hours for the existing commercial on-body infusor.

Approval was supported by achievement of the primary pharmacokinetic endpoint and results showing equivalent urine output, sodium excretion and potassium excretion at six, eight and twelve hours compared with intravenous furosemide. MannKind said the product was generally well tolerated, with a safety profile consistent with known effects of oral and intravenous furosemide. The company expects U.S. commercial availability by the end of August 2026.

The strategic value lies in usability. A rapid at-home treatment may theoretically be deployed before fluid overload worsens and leads to emergency-department visits, hospitalization or readmission. The real opportunity, however, depends on clinical protocols, patient selection, insurance coverage, caregiver education and professional confidence. ReadyFlow is not a new molecule; it is a new delivery method for a familiar diuretic. Its competitive advantage must therefore show up in workflow and economic outcomes, not only in regulatory novelty.

Interpretation: approval removes the nearest binary risk but opens a longer test. Investors should watch onboarding speed, payer coverage, conversion from the on-body infusor, new prescribers and evidence of repeat use.

04 The Cost of Approval: A $45 Million CVR and a $50 Million Private Placement

The scPharmaceuticals acquisition included contingent value rights tied to Furoscix approval and sales. ReadyFlow approval before September 30, 2026 triggered the first milestone, equal to $0.75 per CVR, producing a company-stated obligation of approximately $45 million. This was not an unexpected accounting event; it was an explicit component of the transaction. It matters because it consumes liquidity while MannKind is funding two launches and a broader clinical pipeline.

On July 23 MannKind signed, and on July 24 it closed, an approximately $50 million gross private placement. The company issued 10,440,838 common shares at $3.89 per share and pre-funded warrants to purchase 2,412,632 shares at $3.88, with a $0.01 exercise price. Frazier Life Sciences led the financing. The structure adds approximately 12.85 million potential shares.

Relative to 308.9 million shares outstanding at March 31, the common-stock issuance equals roughly 3.4%; including the pre-funded warrants, the potential increase is approximately 4.2%. The resulting count would be near 321.8 million using only the Q1 base plus the placement, before shares issued for compensation, option exercises, employee plans or other later changes.

The balanced reading is that institutional capital financed a clearly defined obligation connected to a newly de-risked asset, preventing the CVR payment from consuming the full available cash cushion. But the raise is not a transformational recapitalization: the $50 million of gross proceeds is almost entirely offset by the $45 million milestone before fees and expenses. The CVR also retains a second commercial milestone that could create up to roughly another $15 million payment if 2026 trailing Furoscix and ReadyFlow sales reach the contractual levels.

05 Confirmed News Flow: What Actually Changed

06 Why the Stock Matters Now: Q2 Turned Optionality Into an Execution Scorecard

The two major 2026 regulatory events—pediatric Afrezza and ReadyFlow—succeeded, and INFLO-1 added a constructive early clinical readout. The valuation debate can therefore move away from simple binary-event probability and toward measurable operating outcomes: owned-product growth, prescription persistence, product gross margin, SG&A efficiency, operating cash use and reliance on United Therapeutics.

Q2 was encouraging on scale but mixed on quality. Revenue reached a record level, Furoscix grew rapidly and Tyvaso DPI remained resilient. At the same time, Afrezza contracted, consolidated commercial gross margin moved lower with the Furoscix mix, and operating expense absorbed the top-line gain. Investors now have a cleaner framework: growth that does not reduce losses or cash needs deserves a lower quality multiple than growth accompanied by operating leverage.

The next two quarters matter disproportionately. ReadyFlow enters the field in August, pediatric Afrezza gets a fuller launch window, and management’s Furoscix guidance requires a steep second-half acceleration. These are visible KPIs, not distant pipeline assumptions. Positive INFLO-1 data create optionality, but the stock’s near-term proof points are commercial.

07 Company Overview: Four Engines, Four Risk Profiles

MannKind has become a specialty-pharma company with an unusual combination of owned products, royalties, manufacturing services and an inhalation pipeline. Technosphere remains the historic center, but the commercial portfolio no longer depends only on it. Furoscix is a subcutaneous furosemide product acquired with scPharmaceuticals and uses a different drug-device logic. That broadens the business while making the model more complex.

The bull case requires these engines to strengthen together. Strong Tyvaso DPI can fund expansion; pediatric Afrezza can improve the diabetes franchise; ReadyFlow can make Furoscix a more scalable second owned product; nintedanib DPI can show that the platform generates new opportunities. The bear case emerges if one category continues to support everything else while expense and debt remain high.

08 Q2 2026 Earnings Deep Dive: Growth Was Real, Operating Leverage Was Not

Total revenue was $109.4 million, compared with $76.5 million a year earlier and $90.2 million in Q1. Commercial product sales were $42.0 million, collaboration and services revenue was $35.0 million, and royalties were $32.4 million. United Therapeutics contributed approximately 61% of consolidated revenue through royalties, manufacturing and collaboration economics, keeping partner concentration central to the thesis.

The product-level contrast was sharp. Furoscix increased 43% sequentially to $22.2 million, while Afrezza declined 7% year over year to $17.0 million and V-Go declined 33% to $2.8 million. Commercial product gross profit was $27.6 million, equal to a 65.7% margin, reflecting a different and less mature mix than the royalty-heavy consolidated headline.

GAAP EPS was negative $0.06 and adjusted EPS was negative $0.01. The bridge includes $10.2 million of stock-based compensation, $4.4 million of intangible amortization, a $5.0 million contingent-consideration fair-value change and royalty-accounting items. Those adjustments explain much of the gap between GAAP and adjusted results, but not the entire year-over-year deterioration. The cleanest forward KPI is whether revenue can grow faster than SG&A while gross profit converts into operating cash.

09 Afrezza: Pediatric Interest Is Encouraging, but Q2 Revenue Still Fell

Afrezza is rapid-acting inhaled human insulin used at mealtime. On May 29, 2026, the FDA expanded the indication to children and adolescents aged six and older living with diabetes. The label expansion is strategically meaningful, but Q2 included only a partial launch window and Afrezza revenue declined 7% year over year to $17.0 million.

Management reported early signs of pediatric engagement: approximately one-third of the top 100 pediatric rapid-acting insulin writers had prescribed Afrezza, all 20 priority accounts had written prescriptions, and roughly 450 new prescribers had entered since launch—about 200 pediatric and 250 adult. The company also described approximately 1,800 writers since June 1 and said July new-patient volume increased about 30% from June. These are useful leading indicators, but they are company-reported launch metrics rather than durable revenue or refill data.

The practical advantage is intuitive around meals, school, sports and social life. Adoption friction remains real: Afrezza carries a boxed warning for acute bronchospasm in chronic lung disease and requires pulmonary assessment before initiation and periodic monitoring. Payer access, spirometry workflow, dosing education, persistence and the balance between full-time and intermittent use will determine commercial value.

Management indicated that a 2-unit cartridge and InhaleIQ Bluetooth/CGM integration are targeted for 2027, with a higher-concentration Afrezza concept around 2028. Those enhancements could improve usability and dosing flexibility, but they should remain outside the base case until regulatory paths and adoption evidence become clearer.

10 Furoscix and ReadyFlow: Strong Q2 Growth Meets a Demanding Full-Year Guide

Furoscix treats edema caused by fluid overload in adults with chronic heart failure or chronic kidney disease. Q2 net revenue was $22.2 million, up 43% sequentially, while dispensed units increased 49%. Management also cited 36% sequential growth in integrated-delivery-network doses and 67% growth in nephrology, with record prescribing activity.

The FDA-approved ReadyFlow autoinjector delivers 80 mg/mL of subcutaneous furosemide in ten seconds or less, compared with approximately five hours for the existing on-body infusor. Commercial shipments are expected in August following sales-force training. Management expects ReadyFlow to improve the product mix more substantially in 2027 and believes the device can support better gross margins over time.

The guidance math is the main issue. MannKind maintained 2026 Furoscix revenue guidance of $110 million to $120 million. First-half revenue was $37.7 million, leaving $72.3 million to $82.3 million for the second half. The required H2 result equals roughly 1.9 to 2.2 times H1, so the market will need evidence of a step-change rather than a steady continuation of the Q2 run rate.

Easier administration does not automatically change standard of care. Cardiologists, nephrologists, integrated delivery networks and payers must define who should use ReadyFlow, how patients are monitored and whether avoided visits or admissions justify adoption. Coverage, new prescribers, repeat use, conversion from the on-body infusor and product-level gross margin are the next critical KPIs.

11 Tyvaso DPI and United Therapeutics: Resilient Royalty Economics, Persistent Concentration

Tyvaso DPI remains the leading proof point for Technosphere outside diabetes. United Therapeutics commercializes the product, while MannKind receives a contractual royalty on net sales, subject to adjustments and royalty-financing arrangements, plus manufacturing and service revenue.

United reported Q2 Tyvaso DPI sales of $326.6 million, up 4% year over year. Total Tyvaso revenue fell 4% to $452.6 million because nebulized Tyvaso declined 18% to $126.0 million. MannKind’s own Q2 royalty revenue was $32.4 million, up 4% year over year and approximately 1% below Q1. The DPI mix remains favorable to MannKind, but the quarter was stable rather than accelerating.

United accounted for approximately 61% of MannKind’s consolidated Q2 revenue when royalties, collaboration and manufacturing economics are combined. That concentration funds the expansion of owned products and pipeline programs, but it limits strategic control. United’s planned next-generation delivery formats and broader pulmonary-hypertension portfolio could change the mix over time.

The ralinepag DPI collaboration provides a counterweight because it shows United continuing to invest in MannKind’s dry-powder technology. The right conclusion is balanced: Tyvaso DPI is a real, high-value economic engine, but it should not be treated as perpetual, risk-free or fully controlled by MannKind.

12 Nintedanib DPI: INFLO-1 Cleared the Early Safety Test, Not the Efficacy Test

Nintedanib DPI, or MNKD-201, is MannKind’s nearest owned clinical program in idiopathic pulmonary fibrosis. INFLO-1 was a randomized, double-blind, placebo-controlled Phase 1b study in 27 patients at ten U.S. sites, with seven days of dosing. The July 29 update reported no serious adverse events, drug-related gastrointestinal events, bronchospasm, oxygen-saturation concerns, dose reductions or treatment discontinuations.

Cough was the main tolerability signal: approximately 60% of patients had no cough adverse event, about 30% had mild cough and roughly 10% had moderate cough; none were severe and events were described as transient. Across 448 inhalations in patients with IPF, no treatment interruption or discontinuation was attributed to cough. Spirometry did not show a difference between active treatment and placebo during the short study.

Cross-study pharmacokinetic analysis suggested plasma Cmax six to eight times higher than published nebulized nintedanib data at comparable doses. This is hypothesis-supporting exposure evidence, not a randomized head-to-head comparison and not proof of clinical benefit. It should not be translated directly into efficacy or registration probability.

INFLO-2 is the more important next test: a global randomized Phase 2 study targeting approximately 210 patients, with two doses over twelve controlled weeks followed by a 24-week open-label extension. Safety is the primary objective and forced vital capacity is a key efficacy measure. The study permits patients on background therapy or untreated patients. Phase 2 results and FDA dialogue will help determine whether one or two pivotal studies are required.

Interpretation: INFLO-1 reduced near-term inhalation tolerability risk and supported advancement. It did not establish efficacy, differentiation versus oral therapy or a final registration path.

13 Ralinepag DPI and Early Pipeline: Partner Validation, Not Immediate Revenue

Ralinepag DPI, MNKD-1501, is being developed with United Therapeutics for pulmonary hypertension and fibrotic lung diseases. Q2 collaboration revenue included approximately $4.9 million of milestone recognition related to the program. United plans an IND submission by year-end 2026, providing a concrete next regulatory step.

MannKind is eligible for up to $35 million in development milestones and a 10% royalty on net sales, while United expects to be the primary manufacturer. The program strengthens technological validation, but it remains partner-driven and development-stage. It should not be modeled as near-term recurring product revenue.

Earlier options include MNKD-102, a DPI formulation of clofazimine, and other inhaled projects. After the ICoN-1 failure, any MNKD-102 advancement should be judged with discipline: a new formulation and delivery route may change the profile, but they do not erase the futility signal from the nebulized program.

14 ICoN-1/MNKD-101: The Red Flag That Must Stay in the Model

In November 2025 MannKind terminated the global Phase 3 ICoN-1 study of MNKD-101, nebulized clofazimine for NTM lung disease, following a futility determination based on medical monitoring. ClinicalTrials.gov lists the study as terminated with 132 participants actually enrolled.

This matters for two reasons. First, it shows that the inhalation pipeline is not automatically de-risked by the platform. Every drug-device combination must demonstrate clinical efficacy. Second, it reduces the value attributable to the former orphan-lung narrative because the Phase 3 asset is no longer an active catalyst.

MannKind said the outcome does not prevent future consideration of MNKD-102, the dry-powder clofazimine formulation. But “under consideration” is not the same as a funded clinical program. Until a regulatory plan, trial design and timeline exist, MNKD-102 should be treated as low-weight optionality rather than a valuation pillar.

15 Financial Snapshot: $111.1M of Liquidity Before the July Raise—and Before Large Q3 Payments

At June 30, 2026 MannKind held $52.9 million of cash and cash equivalents and $58.2 million of short-term investments, or $111.1 million combined. The company used $23.7 million of operating cash in the first half and approximately $7.0 million for capital expenditures. Working capital also reflects a growing commercial business, including $43.2 million of accounts receivable and $44.4 million of inventory.

The July private placement added approximately $50 million of gross proceeds, suggesting simple pro forma cash and investments near $161 million before fees. That number is not fully discretionary liquidity. ReadyFlow approval triggered an approximately $44.8 million CVR payment due in Q3, and a $5 million Afrezza milestone payment is also expected. After those identified obligations, the economic cushion is materially lower than the gross pro forma headline.

The Blackstone term loan had $325 million of principal and a $319.1 million carrying value at quarter-end, with an effective interest rate of 9.12% and August 2030 maturity. Q2 interest expense was $11.9 million, including acquisition- and milestone-related financing effects. Total liabilities of $799.5 million exceeded total assets of $732.3 million, producing a stockholders’ deficit of $67.2 million.

The liquidity covenant requires at least $40 million of unrestricted cash and cash equivalents in controlled accounts. Current resources and the July placement provide operating flexibility, but launch spending, debt service, milestone payments and working-capital needs make cash conversion a primary quarterly KPI.

16 Capital Structure and Dilution Risk

MannKind had 309,911,682 common shares outstanding at June 30, 2026. The July private placement issued 10,440,838 common shares and pre-funded warrants for 2,412,632 additional shares. The July 24 filing reported 321,540,637 common shares outstanding after the common-stock issuance but before treating the pre-funded warrants as exercised.

Including the pre-funded warrants, the economic share base approaches 324.0 million, approximately 4.5% above the June 30 count before considering stock options, restricted stock units, employee plans or other securities. The warrants carry a $0.01 exercise price and have no expiration date, subject to beneficial-ownership limits, so they are economically close to common equity.

MannKind also retains a fully available at-the-market program of up to $200 million through Cantor Fitzgerald. ATM capacity does not mean issuance is imminent, but it provides a large equity-funding route relative to current liquidity. The investment case must therefore track both operating cash use and per-share value creation, not only consolidated growth.

*illustrative calculation using June 30 common shares plus placement common shares and pre-funded warrants. It excludes later changes, equity compensation, options and other instruments.

17 Management, Execution and Governance

MannKind is led by Michael Castagna, CEO since 2017. Under his leadership the company moved from an almost entirely Afrezza-centered story to a platform containing Tyvaso DPI royalties, the scPharmaceuticals acquisition, Furoscix, ReadyFlow and new dry-powder programs. The transformation is real, but it increased operating and financial complexity.

July Form 4 filings primarily reflected vesting of restricted stock and withholding for tax obligations across executive positions. Those transactions should not automatically be classified as open-market insider selling. Governance should be judged through capital discipline, acquisition quality, KPI transparency, expense control and alignment between compensation and execution.

The placement led by Frazier Life Sciences signals institutional willingness to provide capital, but it does not remove the need for operating results. The company chose equity rather than allowing the CVR to reduce cash by itself; that is defensible, but the cost is dilution.

18 Analyst Snapshot: Positive Ratings, Wide Dispersion

Following ReadyFlow approval, several publicly reported notes maintained favorable views, but the target range shows how differently analysts assess the quality of the economics. H.C. Wainwright reiterated Buy with a $10 target; Wedbush maintained Buy with $8; Truist maintained Buy with $6; RBC maintained Hold with $4.75. These targets are analyst opinions, not intrinsic values or guaranteed forecasts.

The gap between $4.75 and $10 is not a minor detail. It reflects different assumptions on Furoscix peak sales, Tyvaso DPI duration, Afrezza adoption, margins, debt and pipeline value. The assumptions behind the targets are more useful than the final number.

19 Retail Sentiment: Bullish, High-Volume and Still Highly Narrative

The Stocktwits snapshot collected on August 1 showed a sentiment score of 67, a Bullish label, 77.5% bullish-tagged messages and high message volume, with approximately 41,900 watchers. Retail discussion centered on ReadyFlow, Tyvaso DPI royalties, ralinepag and M&A speculation, while bearish posts focused on Afrezza prescriptions, SG&A and frustration with commercial speed.

These data describe attention, not fundamental value. Stocktwits, Reddit and X reflect comments from non-professional traders and investors, can change quickly and are easily influenced by price. Acquisition speculation and extreme price targets are not confirmed facts.

20 Next Catalysts: The Calendar After Q2 and INFLO-1

21 Bull, Base and Bear Scenarios After Q2

22 Risk Register: Red Flags That Remain After the Q2 Growth Headline

Back-half execution risk. Furoscix must generate $72.3 million to $82.3 million in H2 to reach maintained guidance, a major step-up from the first half.

Operating-leverage risk. SG&A rose 84% and adjusted earnings turned negative despite 43% revenue growth.

Commercial adoption risk. Afrezza and ReadyFlow must change clinical behavior. Approval and early prescriber interest do not guarantee durable prescriptions.

Reimbursement risk. Diabetes, heart failure and CKD are payer-driven markets. Prior authorization, formulary placement and gross-to-net can reduce growth quality.

Partner concentration. Approximately 61% of Q2 revenue was linked to United Therapeutics economics, while MannKind does not control the Tyvaso franchise.

Debt and cash-use risk. The $325 million term loan, high interest burden, launch spending and approximately $49.8 million of identified Q3 milestone payments limit flexibility.

Dilution risk. The July placement increased the economic share base; $200 million of ATM capacity and equity compensation remain potential future dilution sources.

Pipeline risk. INFLO-1 was positive on early safety and PK, not efficacy. ICoN-1 was stopped for futility, and INFLO-2 must establish clinical differentiation.

Safety and monitoring. Afrezza requires pulmonary-risk management; Furoscix requires attention to volume, electrolytes, blood pressure and correct administration.

23 Updated Timeline

24 Merlintrader Bottom Line

MannKind’s Q2 was a strong revenue quarter and a weak operating-leverage quarter. The company now has two growing commercial franchises, a resilient royalty stream and a positive early clinical readout. It also has high SG&A, meaningful debt, partner concentration and a demanding second-half Furoscix target.

The key number is not only $109.4 million of revenue. It is the gap between that growth and the negative $2.7 million adjusted result. Furoscix supplied the clearest owned-product momentum, but management’s $110 million to $120 million full-year guidance requires a step-change in H2. ReadyFlow is the mechanism that could enable that acceleration; the launch data must now confirm the thesis.

Afrezza’s pediatric expansion is strategically important, yet Q2 revenue still declined. Early prescriber engagement is encouraging but needs to translate into new-patient growth, refills and better product economics. Tyvaso DPI remains the financial anchor, while INFLO-1 reduced early nintedanib DPI development risk without proving efficacy.

The stock is no longer defined by one pending FDA date. It is defined by a measurable scorecard: Furoscix H2 revenue, ReadyFlow adoption, pediatric Afrezza persistence, Tyvaso DPI stability, SG&A discipline and operating cash use. Sustainable upside requires those metrics to improve together, not simply another quarter of headline revenue growth.

Track upcoming biotech and regulatory dates on the Merlintrader Biotech Catalyst Calendar.

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

25 Get Real-Time Updates

FDA news, PDUFAs, trial data, offerings and biotech catalysts are shared through the Merlintrader Telegram channel.

Primary and reference sources

MannKind Q2 2026 earnings release MannKind Q2 2026 Form 10-Q MannKind Q2 2026 presentation INFLO-1 corporate call transcript United Therapeutics Q2 2026 results ReadyFlow FDA approval · July 24 Private placement · July 24 SEC 8-K · placement and closing Afrezza pediatric approval Breakthrough T1D grant ADA 2026 data Ralinepag DPI collaboration ICoN-1 discontinuation ClinicalTrials.gov ICoN-1 Stocktwits MNKD sentiment snapshot Analyst target snapshot · secondary

This coverage is intended for a general U.S. and international audience and is informational and educational only. It is not independent financial research under applicable rules, personalized advice, solicitation, offer or recommendation. It may include author estimates, interpretations and scenarios that are clearly distinct from confirmed facts. Biotechnology and specialty-pharma securities involve substantial risks of loss, volatility, dilution, trial failure, regulatory delay, weak adoption, reimbursement issues, manufacturing disruption and financing needs. Always verify SEC filings, FDA communications and current official sources.